Video

FUJIFILM Diosynth Biotechnologies Capacity Update October 2024: Large Molecule Drug Substance

Rasmus Pedersen, Ph.D., from FUJIFILM Diosynth Biotechnologies, outlines strategies to expand large-molecule production capacity to meet growing global medicine demand, noting the current gap that leaves 2 billion people without access.

FUJIFILM's global network spans the U.S., UK, Denmark, and Japan, with major investments to scale cell culture and microbial production. Key goals include boosting capacity, speeding tech transfers, increasing flexibility, and enhancing sustainability. Notable facilities include Denmark's 400,000-liter site and a new North Carolina facility modeled after it, both designed for scalable and flexible production from preclinical to commercial stages.

In this presentation, Pedersen likens the modular approach to Lego bricks, enabling adaptable and reliable growth. Learn more about the company's plans to provide clinical and commercial supply of life-changing medicines for patients around the globe by watching video below.

access the Video!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

FUJIFILM Diosynth Biotechnologies